Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 17,807 matching trials from the live ClinicalTrials.gov search.
Filters: Chicago, Illinois Clear all
Completed Phase 1 Interventional

Study of bb21217 in Multiple Myeloma

NCT03274219
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb21217
Biological
Lead sponsor
2seventy bio
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 3 Interventional

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

NCT00017719
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
44
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

NCT00602030
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Interventions
Entinostat, Placebo, Erlotinib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Nov 6, 2026, 5:29 AM EST
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 6, 2026, 5:29 AM EST
Completed Not applicable Interventional

Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement

NCT01501539
View directory record Official record
Conditions
Soft Tissue Inflammation
Interventions
Standard Hydrocolloid Dressing, Silver Hydrocolloid Dressing
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Nov 6, 2026, 5:29 AM EST
Terminated Phase 3 Interventional Results available

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

NCT00520975
View directory record Official record
Conditions
Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
373
States / cities
Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 6, 2026, 5:29 AM EST
Terminated Phase 1 Interventional Results available

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

NCT04865419
View directory record Official record
Conditions
Haematological Malignancies
Interventions
AZD0466, Voriconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Nov 6, 2026, 5:29 AM EST
Not listed Phase 2 Interventional Results available

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03048500
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
Other · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 6, 2026, 5:29 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 3 Interventional Results available

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

NCT02867761
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Indacaterol/Glycopyrrolate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Nov 6, 2026, 5:29 AM EST
Completed Not applicable Interventional Results available

Rheos® Pivotal Trial

NCT00442286
View directory record Official record
Conditions
Hypertension
Interventions
Rheos® Baroreflex Hypertension System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Nov 6, 2026, 5:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pasta Formulations, Portion Sizes and Their Effect on Appetite

NCT01199770
View directory record Official record
Conditions
Healthy, Appetite
Interventions
Control, small, Experimental B, small, Experimental pasta C, small, control, medium, experimental pasta B, medium, experimental pasta C, medium, NL
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

NCT02350569
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Nov 6, 2026, 5:29 AM EST
Active, not recruiting No phase listed Observational

2024 National Survey of Early Care and Education (NSECE)

NCT05987137
View directory record Official record
Conditions
Children Under 13
Interventions
No intervention is being administered.
Other
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
106,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 3 Interventional Results available

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

NCT02184195
View directory record Official record
Conditions
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Gilbert, Arizona • Orange, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 6, 2026, 5:29 AM EST
Terminated Phase 4 Interventional Results available

Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain

NCT02385266
View directory record Official record
Conditions
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
D-Cycloserine, Placebo (for D-cycloserine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Nov 6, 2026, 5:29 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

NCT04533451
View directory record Official record
Conditions
Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
505
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 318 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 6, 2026, 5:29 AM EST
Completed No phase listed Observational

GalaFlex Mesh in Facelift

NCT02053831
View directory record Official record
Conditions
Superficial Musculoaponeurotic System (SMAS) Procedure
Interventions
Not listed
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Ponte Vedra Beach, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Nov 6, 2026, 5:29 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Tobacco Use Disparities Among Low-Income Adults

NCT03077737
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
Choose to Change, Enhanced usual care
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Nov 6, 2026, 5:29 AM EST
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Nov 6, 2026, 5:29 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Nov 6, 2026, 5:29 AM EST
Active, not recruiting No phase listed Observational

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

NCT05297812
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Genetic Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 6, 2026, 5:29 AM EST
Active, not recruiting Phase 3 Interventional

Pivotal Study of Voro Urologic Scaffold

NCT06873581
View directory record Official record
Conditions
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Interventions
Voro Urologic Scaffold
Device
Lead sponsor
Levee Medical, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 6, 2026, 5:29 AM EST